aTyr Pharma Q3 net loss narrows to $18.3 million; prioritizes partners for Phase 3
aTyr Pharma reported a third-quarter 2026 net loss of $18.3 million, or $7.43 per share, down from $25.7 million, or $10.60 per share, a year earlier, with no revenue compared with $190,000 in the prior-year quarter. Cash, cash equivalents, restricted cash and investments totaled $50.3 million at September 30, 2026, down from $80.9 million at December 31, 2025, and the company says this funds operations into late 2028. The company is prioritizing strategic partnerships to advance the proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis, which shifts how that program will be funded.
Key points
- Q3 2026 net loss $18.3 million ($7.43 per share) vs. $25.7 million ($10.60 per share) in Q3 2025
- Q3 2026 revenue was zero vs. $190,000 in Q3 2025; R&D expenses $10.4 million and G&A expenses $8.3 million
- Cash and investments of $50.3 million at September 30, 2026, vs. $80.9 million at December 31, 2025; runway into late 2028
- Reached FDA alignment on the Phase 3 protocol and is prioritizing strategic partnerships and/or licensing arrangements to advance the study
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.